Press

Cybin Announces FDA Investigational New Drug Authorization of Cybin’s Sponsored Feasibility Study using Kernel Flow Technology

Oct 29 • 3 min read

Cybin Inc. (NYSE: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, today announced that the U.S. Food and Drug Administration (“FDA”) has authorized an Investigational New Drug (“IND”) application to proceed with the Company’s sponsored feasibility study using Kernel’s Flow technology to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics. “The word psychedelic means…

MindMed Expands its Drug Development Pipeline with Launch of R(-)-MDMA Program

Oct 29 • 4 min read

Mind Medicine Inc. (NASDAQ: MNMD), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce an expansion of its pipeline with the launch of a program to develop R(-)-MDMA for the treatment of social anxiety and functioning in diagnoses that include Autism Spectrum Disorder (ASD). This program represents a significant expansion and diversification of…

Small Pharma Granted Fast-Track Designation From U.K. Regulator for DMT-Assisted Therapy for Major Depressive Disorder

Oct 22 • 3 min read

Quick Take: Lead candidate SPL026 granted MHRA Innovation Passport Designation Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF), a neuropharmaceutical company focused on psychedelic-assisted therapies, is pleased to announce that following discussions with the U.K. Medicines and Healthcare products Regulatory Agency, Small Pharma has been granted an Innovation Passport Designation for SPL026, the lead product candidate…

Levitee Labs Enters into Credit Facility For Up To $12 Million

Oct 21 • 6 min read

Quick Take: Levitee will utilize the proceeds from the Loan to support their prospective future acquisitions of several assets in the clinics, pharmacies and mental health space as well as for working capital purposes. Levitee Labs Inc. (CSE: LVT) (OTCMKTS: LVTTF), an integrative wellness company with a diversified portfolio of healthcare and wellness assets, is pleased to…

Numinus Advances Phase 1 Trial on Proprietary Psilocybin Product

Oct 20 • 3 min read

Quick Take: Numinus Bioscience has successfully developed PSYBINA™ from Psilocybe species using IP technology related to the production of extracts and downstream derivatives and formulations from Psychoactive Species Cultured Mycelium Numinus Wellness Inc. (TSXV: NUMI), a leader in psychedelics-focused mental healthcare, is pleased to have finalized the study design and protocol for a Phase 1 clinical trial on a naturally…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435